citizen engagement

Blog by Stefaan G. Verhulst and Andrew J. Zahuranec: “For years, public-private partnerships (PPPs) have promised to help governments do more for less. Yet, the discussion and experimentation surrounding PPPs often focus on outdated models and narratives, and the field of experimentation has not fully embraced the opportunities provided by an increasingly networked and data-rich private sector.

Private-sector actors (including businesses and NGOs) have expertise and assets that, if brought to bear in collaboration with the public sector, could spur progress in addressing public problems or providing public services. Challenges to date have largely involved the identification of effective and legitimate means for unlocking the public value of private-sector expertise and assets. Those interested in creating public value through PPPs are faced with a number of questions, including:

How do we broaden and deepen our understanding of PPPs in the 21st Century?
How can we innovate and improve the ways that PPPs tap into private-sector assets and expertise for the public good?
How do we connect actors in the PPP space with open governance developments and practices, especially given that PPPs have not played a major role in the governance innovation space to date?

The PPP Knowledge Lab defines a PPP as a “long-term contract between a private party and a government entity, for providing a public asset or service, in which the private party bears significant risk and management responsibility and remuneration is linked to performance.”…

To maximize the value of PPPs, we don’t just need new tools or experiments but new models for using assets and expertise in different sectors. We need to bring that capacity to public problems.

At the latest convening of the MacArthur Foundation Research Network on Opening Governance, Network members and experts from across the field tried to chart this new course by exploring questions about the future of PPPs.

The group explored the new research and thinking that enables many new types of collaboration beyond the typical “contract” based approaches. Through their discussions, Network members identified four shifts representing ways that cross-sector collaboration could evolve in the future:

From Formal to Informal Trust Mechanisms;
From Selection to Iterative and Inclusive Curation;
From Partnership to Platform; and
From Shared Risk to Shared Outcome….(More)”.

Paper by Marianne Boenink, Lieke van der Scheer, Elisa Garcia and Simone van der Burg in NanoEthics: “Biomedical research policy in recent years has often tried to make such research more ‘translational’, aiming to facilitate the transfer of insights from research and development (R&D) to health care for the benefit of future users. Involving patients in deliberations about and design of biomedical research may increase the quality of R&D and of resulting innovations and thus contribute to translation. However, patient involvement in biomedical research is not an easy feat. This paper discusses the development of a method for involving patients in (translational) biomedical research aiming to address its main challenges.

After reviewing the potential challenges of patient involvement, we formulate three requirements for any method to meaningfully involve patients in (translational) biomedical research. It should enable patients (1) to put forward their experiential knowledge, (2) to develop a rich view of what an envisioned innovation might look like and do, and (3) to connect their experiential knowledge with the envisioned innovation. We then describe how we developed the card-based discussion method ‘Voice of patients’, and discuss to what extent the method, when used in four focus groups, satisfied these requirements. We conclude that the method is quite successful in mobilising patients’ experiential knowledge, in stimulating their imaginaries of the innovation under discussion and to some extent also in connecting these two. More work is needed to translate patients’ considerations into recommendations relevant to researchers’ activities. It also seems wise to broaden the audience for patients’ considerations to other actors working on a specific innovation….(More)”